amaranth

(redirected from Amarantus)
Also found in: Dictionary, Thesaurus, Encyclopedia.

am·a·ranth

, amaranthum (am'ă-ranth, am-ă-ran'thŭm), [C.I. 16185]
An azo dye; a soluble reddish-brown powder that turns magenta red in solution; used as a food, pharmaceutical, and cosmetic coloring agent, and occasionally in histology.
[G. amaranthon, a never-fading flower]

am·a·ranth

(am'ă-ranth)
A weed (Amaranthus) of widespread geographic distribution; some species are consumed as a foodstuff; its prolific ability to produce seed allows its use as a flour. Purported value both internally and externally (e.g., astringent).
Synonym(s): love-lies-bleeding, red cockscomb.
[G. amaranthon, a never-fading flower]
References in periodicals archive ?
The use of funds will be mutually agreed between Amarantus and SeD Biomed.
Commissiong, president and chief executive officer of Amarantus.
Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed scientific publications describing the mechanism of action of eltoprazine for the treatment of PD LID in August of 2015 and December 2016.
Additionally, the companies have entered into a Letter of Intent for Amarantus to assist Anavex in planning the blood-based biomarker components of Anavex' next Phase III trial in Alzheimer's patients.
Generex said Tuesday it would license its RapidMistT technologies to Amarantus, a California biotechnology company, in a $10 million deal including Amarantus stock.
6 June 2016 - US-based biotechnology company Amarantus Bioscience Holdings, Inc.
Affichem SA, AIT Austrian Institute of Technology GmbH, Almac Diagnostics Limited, Amarantus Bioscience Holdings, Inc.
Biotechnology company Amarantus Bioscience Holdings (OtherOTC:AMBS) revealed on Thursday that it has received Australian patent no.
Maximum control of amarantus was for treatment Foramsulfuron these results are supported [3-11-6].
Under the deal, Avant issued to Amarantus 80m shares of common stock of Avant Diagnostics, representing approximately 45% of Avant's post-merger common stock, and 10m additional shares of common stock upon achievement of certain sales milestones.